Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 3/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039814 | 1.00 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL2972762 | 1.00 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15967648 | 0.98 | NPSR1 (0.39) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1357772 | 0.98 | NPSR1 (0.39) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15967647 | 0.98 | NPSR1 (0.39) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL16068191 | 0.94 | NPSR1 (0.44) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL17392829 | 0.92 | NPSR1 (0.42) | NPSR1CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL11954281 | 0.91 | — | — | |
| SCHEMBL11295244 | 0.91 | — | — | |
| SCHEMBL11294916 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215225-A1 | METHOD FOR THE SYNTHESIS OF 5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)BENZOIC ACID, A SODIUM SALT OF SAID ACID AS A SYNTHETIC INTERMEDIATE, AND USE OF THE ACID OR THE SALT THEREOF IN THE PREPARATION OF DARIDOREXANT AND CERTAIN INTERMEDIATES IN THE SYNTHESIS THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-10-16 | — | — | WO | claimed |
| CN-113149826-A | Preparation process of pelubiprofen | 台州市源众药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | claimed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025215225-A1 | METHOD FOR THE SYNTHESIS OF 5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)BENZOIC ACID, A SODIUM SALT OF SAID ACID AS A SYNTHETIC INTERMEDIATE, AND USE OF THE ACID OR THE SALT THEREOF IN THE PREPARATION OF DARIDOREXANT AND CERTAIN INTERMEDIATES IN THE SYNTHESIS THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-10-16 | — | — | WO | disclosed |
| EP-4584247-A2 | HETEROATOM SUBSTITUTED CYCLIC AND ALKYL AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
| US-6943180-B2 | Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | NPSR1 1554/4885CYP4F2 483/4885CYP4A11 740/4885 |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | NPSR1 587/4885CYP4F2 2040/4885CYP4A11 949/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | NPSR1 1486/4885CYP4F2 2227/4885CYP4A11 3884/4885 |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | IL2, TSLP, CD74 | NPSR1 1942/4885CYP4F2 598/4885CYP4A11 1096/4885 |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | PARK7, ADCYAP1R1, LRRK2 | NPSR1 613/4885CYP4F2 4783/4885CYP4A11 4569/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | NPSR1 955/4885CYP4F2 4127/4885CYP4A11 3920/4885 |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | NPSR1 117/4885CYP4F2 4390/4885CYP4A11 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.